Related Experiment Video
Updated: May 20, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal vaccination during pregnancy for preventing infant infection
Surasith Chaithongwongwatthana1, Waralak Yamasmit, Sompop Limpongsanurak
1Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. iamsurasith@gmail.com.
Insights
Pneumococcal vaccination during pregnancy shows no clear benefit in preventing neonatal infections. More research is needed to determine if this approach effectively reduces infant pneumococcal disease.
Area of Science:
- Public Health
- Pediatrics
- Immunology
Background:
- Pneumococcal infections cause over a million childhood deaths annually, with antimicrobial resistance complicating treatment.
- Newborn vaccination is effective for older infants but not for those under three months.
- Vaccinating pregnant women may offer protection to newborns before their own vaccination takes effect.
Purpose of the Study:
- To evaluate the impact of pneumococcal vaccination during pregnancy on preventing infant infections.
Main Methods:
- Searched the Cochrane Pregnancy and Childbirth Group's Trials Register and reference lists.
- Included randomized controlled trials comparing pneumococcal vaccine in pregnant women versus placebo or other vaccines.
- Two reviewers independently assessed trials, extracted data, and checked accuracy.
Main Results:
- Five trials with 579 participants were analyzed.
- No evidence showed pneumococcal vaccination in pregnancy reduced neonatal infection risk (RR 0.66, 95% CI 0.30 to 1.46).
- Limited evidence suggested reduced infant pneumococcal colonization by 16 months (RR 0.33, 95% CI 0.11 to 0.98), but not at 2-7 months. No significant difference in injection site tenderness was observed.
Conclusions:
- Insufficient evidence exists to confirm if pneumococcal vaccination during pregnancy effectively reduces infant infections.
Background:
Each year at least one million children worldwide die of pneumococcal infections. The development of bacterial resistance to antimicrobials adds to the difficulty of treatment of diseases and emphasizes the need for a preventive approach. Newborn vaccination schedules could substantially reduce the impact of pneumococcal disease in immunized children, but does not have an effect on the morbidity and mortality of infants less than three months of age. Pneumococcal vaccination during pregnancy may be a way of preventing pneumococcal disease during the first months of life before the pneumococcal vaccine administered to the infant starts to produce protection.
Objectives:
To assess the effect of pneumococcal vaccination during pregnancy for preventing infant infection.
Search Methods:
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2011) and reference lists of retrieved studies.
Selection Criteria:
Randomized controlled trials in pregnant women comparing pneumococcal vaccine with placebo or doing nothing or with another vaccine to prevent infant infections.
Data Collection And Analysis:
Two review authors independently assessed trials for inclusion, methodological quality and extracted data using a data collection form. Data were checked for accuracy. We contacted study authors for additional information.
Main Results:
Seven trials were included, but only five trials (579 participants) contributed data. There was no evidence that pneumococcal vaccination during pregnancy reduces the risk of neonatal infection (risk ratio (RR) 0.66; 95% confidence interval (CI) 0.30 to 1.46; two trials, 241 pregnancies). Although the data suggest an effect in reducing pneumococcal colonization in infants by 16 months of age (RR 0.33; 95% CI 0.11 to 0.98; one trial, 56 pregnancies), there was no evidence of this effect in infants at two to three months of age (RR 1.13; 95% CI 0.46 to 2.78; two trials, 146 pregnancies) or by six to seven months of age (RR 0.66; 95% CI 0.20 to 2.17; two trials, 144 pregnancies). No significant difference for tenderness at the injection site between women who received pneumococcal vaccine and those who received control vaccine (RR 3.20; 95% CI 0.32 to 31.54; two trials, 130 women).
Authors' Conclusions:
There is insufficient evidence to assess whether pneumococcal vaccination during pregnancy could reduce infant infections.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...